Concepts (176)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Angelman Syndrome | 18 | 2022 | 139 | 5.880 |
Why?
|
| Seizures | 16 | 2023 | 3000 | 1.870 |
Why?
|
| Anticonvulsants | 13 | 2023 | 1921 | 1.450 |
Why?
|
| Epilepsies, Myoclonic | 3 | 2018 | 83 | 1.190 |
Why?
|
| Trisomy | 3 | 2015 | 259 | 0.940 |
Why?
|
| Chromosomes, Human, Pair 15 | 8 | 2020 | 360 | 0.830 |
Why?
|
| Glycemic Index | 2 | 2017 | 400 | 0.790 |
Why?
|
| Spasms, Infantile | 2 | 2023 | 302 | 0.770 |
Why?
|
| Electroencephalography | 15 | 2022 | 6273 | 0.720 |
Why?
|
| GABA Agonists | 1 | 2020 | 105 | 0.700 |
Why?
|
| Epilepsy | 12 | 2019 | 3320 | 0.650 |
Why?
|
| Isoxazoles | 1 | 2020 | 234 | 0.630 |
Why?
|
| Gastrointestinal Diseases | 2 | 2017 | 1203 | 0.570 |
Why?
|
| Diazepam | 1 | 2018 | 215 | 0.550 |
Why?
|
| Phenylalanine-tRNA Ligase | 1 | 2016 | 15 | 0.530 |
Why?
|
| Meningoencephalitis | 1 | 2014 | 82 | 0.450 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 2018 | 896 | 0.420 |
Why?
|
| Status Epilepticus | 1 | 2018 | 460 | 0.400 |
Why?
|
| Hospitals, General | 1 | 2016 | 802 | 0.380 |
Why?
|
| Encephalitis | 1 | 2014 | 441 | 0.350 |
Why?
|
| Child, Preschool | 22 | 2021 | 42500 | 0.350 |
Why?
|
| Mitochondrial Proteins | 1 | 2016 | 975 | 0.340 |
Why?
|
| Autoantibodies | 1 | 2018 | 2113 | 0.330 |
Why?
|
| Diet, Carbohydrate-Restricted | 1 | 2012 | 263 | 0.320 |
Why?
|
| Heterozygote | 1 | 2016 | 2794 | 0.320 |
Why?
|
| Hernia | 1 | 2008 | 67 | 0.310 |
Why?
|
| Delta Rhythm | 2 | 2021 | 81 | 0.300 |
Why?
|
| Frontal Lobe | 1 | 2014 | 1410 | 0.300 |
Why?
|
| Anxiety | 3 | 2021 | 4671 | 0.280 |
Why?
|
| Ambulatory Care | 1 | 2018 | 2778 | 0.270 |
Why?
|
| Child | 25 | 2023 | 80564 | 0.270 |
Why?
|
| Adolescent | 23 | 2021 | 88835 | 0.270 |
Why?
|
| Syndrome | 3 | 2022 | 3271 | 0.250 |
Why?
|
| Infarction, Middle Cerebral Artery | 1 | 2008 | 485 | 0.240 |
Why?
|
| Infant | 13 | 2023 | 36386 | 0.240 |
Why?
|
| Data Collection | 1 | 2014 | 3318 | 0.230 |
Why?
|
| Massachusetts | 4 | 2018 | 8875 | 0.220 |
Why?
|
| Constipation | 2 | 2018 | 568 | 0.190 |
Why?
|
| Treatment Outcome | 9 | 2023 | 65188 | 0.180 |
Why?
|
| Ambulatory Care Facilities | 2 | 2018 | 939 | 0.180 |
Why?
|
| Male | 33 | 2021 | 363698 | 0.180 |
Why?
|
| Young Adult | 12 | 2021 | 59889 | 0.180 |
Why?
|
| Mutation | 7 | 2019 | 30198 | 0.170 |
Why?
|
| Sleep | 1 | 2016 | 4813 | 0.170 |
Why?
|
| Brain | 6 | 2019 | 27171 | 0.170 |
Why?
|
| Brain Diseases | 1 | 2008 | 1546 | 0.160 |
Why?
|
| Fumarate Hydratase | 1 | 2019 | 55 | 0.160 |
Why?
|
| Chromosome Duplication | 2 | 2019 | 79 | 0.160 |
Why?
|
| Female | 32 | 2021 | 396112 | 0.160 |
Why?
|
| Hyperventilation | 1 | 2019 | 78 | 0.160 |
Why?
|
| Humans | 44 | 2023 | 765968 | 0.160 |
Why?
|
| Psychomotor Disorders | 1 | 2019 | 149 | 0.160 |
Why?
|
| Buspirone | 1 | 2019 | 80 | 0.150 |
Why?
|
| Piracetam | 2 | 2009 | 88 | 0.150 |
Why?
|
| Muscle Hypotonia | 1 | 2019 | 167 | 0.150 |
Why?
|
| Retrospective Studies | 13 | 2018 | 81514 | 0.150 |
Why?
|
| Drug Administration Schedule | 2 | 2020 | 4850 | 0.150 |
Why?
|
| Chromosome Aberrations | 4 | 2019 | 1774 | 0.140 |
Why?
|
| Double-Blind Method | 2 | 2023 | 12437 | 0.140 |
Why?
|
| Metabolism, Inborn Errors | 1 | 2019 | 291 | 0.140 |
Why?
|
| Ubiquitin-Protein Ligases | 5 | 2021 | 1892 | 0.140 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2018 | 36532 | 0.140 |
Why?
|
| Adult | 16 | 2023 | 223044 | 0.140 |
Why?
|
| Facies | 2 | 2019 | 223 | 0.140 |
Why?
|
| Blood Chemical Analysis | 1 | 2018 | 433 | 0.130 |
Why?
|
| Phenotype | 6 | 2022 | 16721 | 0.130 |
Why?
|
| Electrodiagnosis | 1 | 2016 | 149 | 0.130 |
Why?
|
| KCNQ2 Potassium Channel | 1 | 2015 | 19 | 0.120 |
Why?
|
| Senna Extract | 1 | 2015 | 3 | 0.120 |
Why?
|
| Bisacodyl | 1 | 2015 | 12 | 0.120 |
Why?
|
| Vomiting | 1 | 2018 | 647 | 0.120 |
Why?
|
| Uniparental Disomy | 1 | 2014 | 46 | 0.120 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2016 | 3672 | 0.120 |
Why?
|
| Dysarthria | 1 | 2014 | 57 | 0.120 |
Why?
|
| Enema | 1 | 2015 | 140 | 0.110 |
Why?
|
| Tuberous Sclerosis | 2 | 2013 | 1038 | 0.110 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2018 | 669 | 0.110 |
Why?
|
| Puerto Rico | 1 | 2014 | 381 | 0.110 |
Why?
|
| Diagnosis, Differential | 3 | 2019 | 12976 | 0.110 |
Why?
|
| Autistic Disorder | 2 | 2013 | 1239 | 0.110 |
Why?
|
| Chromosome Disorders | 1 | 2016 | 498 | 0.100 |
Why?
|
| Drug Therapy, Combination | 1 | 2023 | 6309 | 0.100 |
Why?
|
| Disease Management | 3 | 2019 | 2535 | 0.100 |
Why?
|
| DNA Copy Number Variations | 2 | 2019 | 2045 | 0.100 |
Why?
|
| Chromosomes | 1 | 2016 | 578 | 0.100 |
Why?
|
| Biopolymers | 1 | 2013 | 181 | 0.100 |
Why?
|
| Malformations of Cortical Development | 1 | 2014 | 174 | 0.100 |
Why?
|
| Ocular Motility Disorders | 1 | 2014 | 144 | 0.100 |
Why?
|
| Age Distribution | 1 | 2018 | 2858 | 0.100 |
Why?
|
| Ataxia | 1 | 2014 | 307 | 0.090 |
Why?
|
| Fatal Outcome | 1 | 2016 | 1831 | 0.090 |
Why?
|
| Valproic Acid | 2 | 2016 | 445 | 0.090 |
Why?
|
| Scoliosis | 1 | 2018 | 789 | 0.090 |
Why?
|
| Cohort Studies | 6 | 2019 | 41649 | 0.090 |
Why?
|
| Prevalence | 2 | 2018 | 15842 | 0.090 |
Why?
|
| Gastroesophageal Reflux | 1 | 2018 | 833 | 0.090 |
Why?
|
| Social Adjustment | 1 | 2012 | 633 | 0.090 |
Why?
|
| Genetic Diseases, X-Linked | 1 | 2014 | 385 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2020 | 10729 | 0.080 |
Why?
|
| Microcephaly | 1 | 2014 | 426 | 0.080 |
Why?
|
| Health Surveys | 2 | 2018 | 4056 | 0.080 |
Why?
|
| Pilot Projects | 1 | 2023 | 8733 | 0.080 |
Why?
|
| Immunologic Factors | 1 | 2018 | 1587 | 0.080 |
Why?
|
| Canada | 1 | 2014 | 2119 | 0.080 |
Why?
|
| Polyethylene Glycols | 1 | 2015 | 1188 | 0.080 |
Why?
|
| Clonazepam | 1 | 2009 | 134 | 0.080 |
Why?
|
| Intelligence | 1 | 2012 | 923 | 0.070 |
Why?
|
| Parent-Child Relations | 1 | 2012 | 774 | 0.070 |
Why?
|
| Child Behavior Disorders | 1 | 2012 | 814 | 0.070 |
Why?
|
| Triazines | 1 | 2009 | 307 | 0.070 |
Why?
|
| Bhutan | 2 | 2017 | 61 | 0.070 |
Why?
|
| Epilepsy, Generalized | 1 | 2009 | 183 | 0.070 |
Why?
|
| Drug Prescriptions | 1 | 2016 | 1662 | 0.070 |
Why?
|
| Drug Tolerance | 1 | 2008 | 363 | 0.070 |
Why?
|
| Evaluation Studies as Topic | 1 | 2008 | 1600 | 0.060 |
Why?
|
| Vagus Nerve Stimulation | 1 | 2009 | 228 | 0.060 |
Why?
|
| Activities of Daily Living | 1 | 2014 | 2415 | 0.060 |
Why?
|
| Cognition | 1 | 2021 | 7049 | 0.050 |
Why?
|
| Cerebral Angiography | 1 | 2008 | 1262 | 0.050 |
Why?
|
| Drug Resistance | 1 | 2009 | 1591 | 0.050 |
Why?
|
| Prognosis | 3 | 2017 | 29922 | 0.050 |
Why?
|
| Hippocampus | 1 | 2014 | 3775 | 0.050 |
Why?
|
| Cerebral Cortex | 1 | 2016 | 5767 | 0.040 |
Why?
|
| Myocardium | 1 | 2013 | 4760 | 0.040 |
Why?
|
| Quality of Life | 2 | 2018 | 13462 | 0.040 |
Why?
|
| Middle Aged | 5 | 2020 | 223009 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2014 | 8067 | 0.040 |
Why?
|
| Receptor, Serotonin, 5-HT1A | 1 | 2019 | 57 | 0.040 |
Why?
|
| Genomic Imprinting | 1 | 2020 | 326 | 0.040 |
Why?
|
| Infant, Newborn | 3 | 2019 | 26346 | 0.040 |
Why?
|
| Follow-Up Studies | 2 | 2017 | 39193 | 0.040 |
Why?
|
| Blood Glucose | 1 | 2012 | 6424 | 0.040 |
Why?
|
| Comorbidity | 2 | 2009 | 10563 | 0.040 |
Why?
|
| Psychiatric Status Rating Scales | 2 | 2021 | 6014 | 0.040 |
Why?
|
| Standard of Care | 1 | 2022 | 567 | 0.040 |
Why?
|
| Pediatrics | 1 | 2012 | 3606 | 0.030 |
Why?
|
| Phenytoin | 1 | 2016 | 189 | 0.030 |
Why?
|
| Carbamazepine | 1 | 2016 | 222 | 0.030 |
Why?
|
| Serotonin | 1 | 2019 | 1049 | 0.030 |
Why?
|
| Advisory Committees | 1 | 2018 | 796 | 0.030 |
Why?
|
| Cognition Disorders | 2 | 2018 | 3967 | 0.030 |
Why?
|
| Genotype | 2 | 2020 | 13024 | 0.030 |
Why?
|
| Disease Susceptibility | 1 | 2019 | 1789 | 0.020 |
Why?
|
| Prospective Studies | 2 | 2017 | 54802 | 0.020 |
Why?
|
| Pedigree | 1 | 2019 | 4526 | 0.020 |
Why?
|
| Gene Duplication | 1 | 2013 | 317 | 0.020 |
Why?
|
| Body Fat Distribution | 1 | 2013 | 246 | 0.020 |
Why?
|
| Angiomyolipoma | 1 | 2013 | 190 | 0.020 |
Why?
|
| Abdominal Neoplasms | 1 | 2013 | 284 | 0.020 |
Why?
|
| Disease Progression | 1 | 2008 | 13632 | 0.020 |
Why?
|
| Movement Disorders | 1 | 2015 | 461 | 0.020 |
Why?
|
| Pharmacogenetics | 1 | 2015 | 682 | 0.020 |
Why?
|
| Heart Neoplasms | 1 | 2013 | 375 | 0.020 |
Why?
|
| Chromosome Deletion | 1 | 2014 | 1385 | 0.020 |
Why?
|
| Epilepsy, Absence | 1 | 2009 | 50 | 0.020 |
Why?
|
| Caregivers | 1 | 2021 | 2307 | 0.020 |
Why?
|
| Online Systems | 1 | 2009 | 181 | 0.020 |
Why?
|
| Anxiety Disorders | 1 | 2019 | 2737 | 0.020 |
Why?
|
| Parents | 1 | 2021 | 3592 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 8529 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2013 | 2505 | 0.020 |
Why?
|
| United States | 1 | 2014 | 72903 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2008 | 1377 | 0.020 |
Why?
|
| Genetic Testing | 1 | 2019 | 3595 | 0.020 |
Why?
|
| Epilepsies, Partial | 1 | 2009 | 431 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2021 | 15398 | 0.010 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2013 | 2796 | 0.010 |
Why?
|
| Severity of Illness Index | 2 | 2012 | 15880 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2010 | 4108 | 0.010 |
Why?
|
| Age Factors | 1 | 2019 | 18380 | 0.010 |
Why?
|
| Animals | 1 | 2013 | 168764 | 0.010 |
Why?
|
| Heart | 1 | 2013 | 4414 | 0.010 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2009 | 1090 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2013 | 20659 | 0.010 |
Why?
|
| Risk Factors | 1 | 2013 | 74840 | 0.000 |
Why?
|
| Aged | 1 | 2016 | 171117 | 0.000 |
Why?
|
Concepts
(176)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(37)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_